Connect
Of possible interest re raloxifene
A real‑world pharmacovigilance study of raloxifene based on the FDA adverse event reporting system
Our study reaffirmed some existing safety information regarding raloxifene while also unveiling novel risk signals. The findings provided crucial insights to enhance the rational use of the drug and inform safety regulatory strategies.
Our study reaffirmed some existing safety information regarding raloxifene while also unveiling novel risk signals. The findings provided crucial insights to enhance the rational use of the drug and inform safety regulatory strategies.
Keywords: FAERS database; Raloxifene; adverse events; osteoporosis; pharmacovigilance; real-world data analysis.
Like
Helpful
HugInterested in more discussions like this? Go to the Osteoporosis & Bone Health Support Group.
Connect
@tillymack It looks like you copied the abstract from an article. Could you please post where you found this article? I'd like to know the names of the authors and where this study was published.
@naturegirl5 I found the abstract in the Pubmed database (Pubmed.gov). You can find the full abstract (but not full text of the article) by searching the PMID 39690869 or copy and paste the title in the search box.
Please tell us what the new safety concerns are
@daisylou This item caught my attention because I took raloxifene for many years. I do have osteoporosis and scoliosis and one of the keywords for this article is osteoporosis. I did not pay for the entire article.